TNFRSF8 and peripheral T-cell lymphoma, not otherwise specified: In addition to cHL, BV has shown to be highly effective in other CD30-positive neoplasms, such as peripheral T-cell lymphomas (PTCL), systemic anaplastic large cell lymphoma (sALCL), primary cutaneous anaplastic large cell lymphoma (pcALCL), and CD30-expressing mycosis fungoides (MF) [8,9,10,11].